Kallyope is a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis.
Kallyope, headquartered at the Alexandria Center® for Life Science in New York City, is a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. The company’s cross-disciplinary team integrates advanced technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that leads to transformational therapeutics to improve human health. The company’s founders are Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D., and Nobel laureate Richard Axel, M.D. For more information, visit www.kallyope.com.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 15, 2022 | Series D | $236M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hartford HealthCare Endowment | — | Series D |